Mineralys Therapeutics (MLYS) Expected to Release Earnings on Wednesday

Mineralys Therapeutics (NASDAQ:MLYS) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Mineralys Therapeutics to announce earnings of ($0.5548) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.30). On average, analysts expect Mineralys Therapeutics to post ($4.45) EPS for the current fiscal year and ($1.92) EPS for the next fiscal year.

Mineralys Therapeutics Stock Performance

Mineralys Therapeutics stock traded up $0.28 during mid-day trading on Tuesday, reaching $15.83. 557,598 shares of the stock traded hands, compared to its average volume of 1,318,623. Mineralys Therapeutics has a 12-month low of $15.33 and a 12-month high of $47.65. The business’s 50-day moving average is $24.57 and its 200-day moving average is $26.94. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. The stock has a market capitalization of $1.40 billion, a PE ratio of -3.72 and a beta of 0.69.

Insider Transactions at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 75,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $25.46, for a total transaction of $1,909,500.00. Following the completion of the sale, the chief executive officer owned 528,621 shares of the company’s stock, valued at $13,458,690.66. This represents a 12.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 7,438 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $28.12, for a total transaction of $209,156.56. Following the completion of the sale, the insider owned 38,400 shares of the company’s stock, valued at approximately $1,079,808. This trade represents a 16.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 199,365 shares of company stock worth $5,461,854. 18.94% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MLYS. Zacks Research raised shares of Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. HC Wainwright restated a “buy” rating and issued a $56.00 price target on shares of Mineralys Therapeutics in a report on Monday, October 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, October 15th. UBS Group initiated coverage on shares of Mineralys Therapeutics in a research note on Sunday, October 11th. They set a “neutral” rating and a $29.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $45.50.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company’s research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys’ lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.